Fig 1: HT up-regulates Nrf2 both in normoxic and hypoxic conditions.(A) Transcriptional levels of Nrf2 in HT-treated (0–200 µM) normoxic and hypoxic cells. Effect of HT 200 µM on: (B) Nrf2 protein expression, (C, D) mRNA levels of the Nrf2 target genes GSTA2 and HO-1, (E) GSTA2 activity, and (F) HO-1 protein level. The mRNA results are expressed as relative to normoxic non HT-treated cells after normalization against PPIA. Densitometric quantification of Nrf2 protein is shown as relative to a-tubulin (a-Tub). A representative immunoblot from a single experiment is shown. Values represent the mean ± SD from three independent experiments. Statistically significant differences with the corresponding non-treated normoxic cells: * p<0.05, ** p<0.01, *** p<0.001. Statistically significant differences with the corresponding non-treated hypoxic cells: # p<0.05, ## p<0.01, ### p<0.001.
Fig 2: Nrf2 silencing reduces GSTA2 but not HO-1 mRNA levels.(A) Knockdown of Nrf2 with siNrf2 in control and HT-treated (200 µM) normoxic and hypoxic cells. The results are expressed as mRNA level relative to normoxic scr siRNA/non HT-treated cells after normalization against PPIA. (B) Effect of Nrf2-silencing on the transcription level of GSTA2 and HO-1 in normoxic and hypoxic cells after treatment with HT 200 µM. The results are expressed as mRNA levels relative to normoxic HT-treated cells after normalization against PPIA. Values represent the mean ± SD from three independent experiments. Statistically significant differences with the corresponding non-treated normoxic cells: * p<0.05, ** p<0.01. Statistically significant differences with the corresponding non-treated hypoxic cells: # p<0.05, ## p<0.01. Statistically significant differences with the corresponding Nrf2-silenced non-HT-treated cells: a p<0.05. Statistically significant differences with the corresponding non-Nrf2-silenced HT-treated cells: b p<0.05.
Supplier Page from CUSABIO Technology LLC for Human heme oxygenase 1,HO-1 ELISA Kit